AU2400692A - Trifunctional compounds having specificity for multi-drug resistant cells - Google Patents

Trifunctional compounds having specificity for multi-drug resistant cells

Info

Publication number: AU2400692A
Authority: AU; Australia
Prior art keywords: fab; agent; trifunctional compound; compound; moiety
Prior art date: 1991-07-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU24006/92A

Other languages

English (en)

Inventor

Clarence N Ahlem

Lana S Grauer

Ann E. Huang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hybritech Inc

Original Assignee

Hybritech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-19

Filing date

1992-07-17

Publication date

1993-02-23

1992-07-17 Application filed by Hybritech Inc filed Critical Hybritech Inc

1993-02-23 Publication of AU2400692A publication Critical patent/AU2400692A/en

Status Abandoned legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims description 154
239000003814 drug Substances 0.000 title claims description 105
229940079593 drug Drugs 0.000 title claims description 60
238000000034 method Methods 0.000 claims description 66
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 53
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 52
229940124597 therapeutic agent Drugs 0.000 claims description 45
239000000032 diagnostic agent Substances 0.000 claims description 41
229940039227 diagnostic agent Drugs 0.000 claims description 41
230000036457 multidrug resistance Effects 0.000 claims description 38
230000009257 reactivity Effects 0.000 claims description 35
230000027455 binding Effects 0.000 claims description 33
206010028980 Neoplasm Diseases 0.000 claims description 30
241000124008 Mammalia Species 0.000 claims description 29
239000002738 chelating agent Substances 0.000 claims description 26
-1 99nTc Chemical compound 0.000 claims description 21
239000012216 imaging agent Substances 0.000 claims description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
208000035475 disorder Diseases 0.000 claims description 18
230000000694 effects Effects 0.000 claims description 13
229910021645 metal ion Inorganic materials 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 13
230000005298 paramagnetic effect Effects 0.000 claims description 12
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 9
229940127089 cytotoxic agent Drugs 0.000 claims description 8
239000002254 cytotoxic agent Substances 0.000 claims description 8
231100000599 cytotoxic agent Toxicity 0.000 claims description 8
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 8
230000003034 chemosensitisation Effects 0.000 claims description 7
239000006114 chemosensitizer Substances 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 7
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 6
239000003153 chemical reaction reagent Substances 0.000 claims description 6
239000003431 cross linking reagent Substances 0.000 claims description 6
229960000640 dactinomycin Drugs 0.000 claims description 5
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
150000004697 chelate complex Chemical class 0.000 claims description 4
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 4
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
108010092160 Dactinomycin Proteins 0.000 claims description 3
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 3
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 3
229960004528 vincristine Drugs 0.000 claims description 3
LWFDUMPGOAKHKC-UHFFFAOYSA-N C1=CC=C2C=C(C(=O)C(C(O)=C3O)=O)C3=CC2=C1 Chemical compound C1=CC=C2C=C(C(=O)C(C(O)=C3O)=O)C3=CC2=C1 LWFDUMPGOAKHKC-UHFFFAOYSA-N 0.000 claims description 2
108010026389 Gramicidin Proteins 0.000 claims description 2
229930012538 Paclitaxel Natural products 0.000 claims description 2
GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 claims description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 claims description 2
229960001338 colchicine Drugs 0.000 claims description 2
GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 claims description 2
GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 claims description 2
229960000975 daunorubicin Drugs 0.000 claims description 2
CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 2
229960004679 doxorubicin Drugs 0.000 claims description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims description 2
229960005542 ethidium bromide Drugs 0.000 claims description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
229960005420 etoposide Drugs 0.000 claims description 2
229910052747 lanthanoid Inorganic materials 0.000 claims description 2
150000002602 lanthanoids Chemical class 0.000 claims description 2
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 2
229960004857 mitomycin Drugs 0.000 claims description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
229960001156 mitoxantrone Drugs 0.000 claims description 2
229960001592 paclitaxel Drugs 0.000 claims description 2
229960003171 plicamycin Drugs 0.000 claims description 2
229950010131 puromycin Drugs 0.000 claims description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
229960001278 teniposide Drugs 0.000 claims description 2
229910052723 transition metal Inorganic materials 0.000 claims description 2
150000003624 transition metals Chemical class 0.000 claims description 2
229960003048 vinblastine Drugs 0.000 claims description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
210000004027 cell Anatomy 0.000 description 74
239000012634 fragment Substances 0.000 description 26
239000000243 solution Substances 0.000 description 24
108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 23
102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 23
229910052738 indium Inorganic materials 0.000 description 15
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 15
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 13
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
238000002835 absorbance Methods 0.000 description 11
239000000427 antigen Substances 0.000 description 11
230000000890 antigenic effect Effects 0.000 description 11
108091007433 antigens Proteins 0.000 description 11
102000036639 antigens Human genes 0.000 description 11
238000001514 detection method Methods 0.000 description 11
238000003786 synthesis reaction Methods 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 10
201000011510 cancer Diseases 0.000 description 10
229960003330 pentetic acid Drugs 0.000 description 10
230000001675 anti-mdr Effects 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 8
239000000872 buffer Substances 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
239000012528 membrane Substances 0.000 description 8
239000000523 sample Substances 0.000 description 8
210000004408 hybridoma Anatomy 0.000 description 7
210000004881 tumor cell Anatomy 0.000 description 7
241000699670 Mus sp. Species 0.000 description 6
238000003384 imaging method Methods 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
230000001588 bifunctional effect Effects 0.000 description 5
PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
PSCMQHVBLHHWTO-UHFFFAOYSA-K indium(iii) chloride Chemical compound Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
241001529936 Murinae Species 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
238000003556 assay Methods 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
238000012544 monitoring process Methods 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
125000003396 thiol group Chemical group [H]S* 0.000 description 4
241000282412 Homo Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
229920005654 Sephadex Polymers 0.000 description 3
239000012507 Sephadex™ Substances 0.000 description 3
239000013522 chelant Substances 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
239000012737 fresh medium Substances 0.000 description 3
230000004927 fusion Effects 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
238000011503 in vivo imaging Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
230000007154 intracellular accumulation Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
239000008399 tap water Substances 0.000 description 3
235000020679 tap water Nutrition 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
150000003923 2,5-pyrrolediones Chemical class 0.000 description 2
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
WADOMFYNYYEBBV-UHFFFAOYSA-N 3-(4-aminophenyl)-2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]propanoic acid Chemical compound NC1=CC=C(CC(N(CCN(CC(O)=O)CC(O)=O)CC(O)=O)C(O)=O)C=C1 WADOMFYNYYEBBV-UHFFFAOYSA-N 0.000 description 2
GFZXQBDELXEPTQ-UHFFFAOYSA-N 3-[(3-carboxy-2-nitrophenyl)disulfanyl]-2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC(SSC=2C(=C(C(O)=O)C=CC=2)[N+]([O-])=O)=C1[N+]([O-])=O GFZXQBDELXEPTQ-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
241001494479 Pecora Species 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
208000006265 Renal cell carcinoma Diseases 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000007598 dipping method Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000002595 magnetic resonance imaging Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
238000011580 nude mouse model Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
238000011533 pre-incubation Methods 0.000 description 2
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
229960001722 verapamil Drugs 0.000 description 2
DTRVZAALOQTDSF-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-phenylpropyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=CC=C1 DTRVZAALOQTDSF-UHFFFAOYSA-N 0.000 description 1
WYMDDFRYORANCC-UHFFFAOYSA-N 2-[[3-[bis(carboxymethyl)amino]-2-hydroxypropyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)CN(CC(O)=O)CC(O)=O WYMDDFRYORANCC-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
239000004280 Sodium formate Substances 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
241001428384 Zamora Species 0.000 description 1
TYXNQDAIWMHZAY-UHFFFAOYSA-N [C].NC(N)=O Chemical compound [C].NC(N)=O TYXNQDAIWMHZAY-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
201000005179 adrenal carcinoma Diseases 0.000 description 1
201000005188 adrenal gland cancer Diseases 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
238000007818 agglutination assay Methods 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
229940033495 antimalarials Drugs 0.000 description 1
150000004982 aromatic amines Chemical group 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000834 fixative Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
RJMMFJHMVBOLGY-UHFFFAOYSA-N indium(3+) Chemical compound [In+3] RJMMFJHMVBOLGY-UHFFFAOYSA-N 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000010829 isocratic elution Methods 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000029986 neuroepithelioma Diseases 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000005375 photometry Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000003910 polypeptide antibiotic agent Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
238000002600 positron emission tomography Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000002603 single-photon emission computed tomography Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
235000019254 sodium formate Nutrition 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
238000012800 visualization Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Radiology & Medical Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Optics & Photonics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AU24006/92A 1991-07-19 1992-07-17 Trifunctional compounds having specificity for multi-drug resistant cells Abandoned AU2400692A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73296991A	1991-07-19	1991-07-19
US732969		1991-07-19

Publications (1)

Publication Number	Publication Date
AU2400692A true AU2400692A (en)	1993-02-23

Family

ID=24945654

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU24006/92A Abandoned AU2400692A (en)	1991-07-19	1992-07-17	Trifunctional compounds having specificity for multi-drug resistant cells

Country Status (4)

Country	Link
EP (1)	EP0596011A1 (fr)
AU (1)	AU2400692A (fr)
CA (1)	CA2113578A1 (fr)
WO (1)	WO1993002105A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0569141A3 (fr) *	1992-04-14	1994-10-26	Hybritech Inc	Inhibition de la croissance des tumeurs multirésistantes aux médicaments à l'aide d'anticorps.
US5342926A (en) *	1993-06-08	1994-08-30	The Regents Of The University Of California	Analogs of cytochalasin B as radiopharmaceuticals for nuclear imaging of trans-membrane glucose transport
US5686578A (en)	1994-08-05	1997-11-11	Immunomedics, Inc.	Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
DE19505960A1 (de)	1995-02-21	1996-08-22	Deutsches Krebsforsch	Konjugat zur individuellen Dosierung von Arzneimitteln
DE19531348A1 (de) *	1995-08-25	1997-02-27	Gsf Forschungszentrum Umwelt	Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo
US20010023288A1 (en)	1999-07-07	2001-09-20	Wilbur D. Scott	Trifunctional reagent for conjugation to a biomolecule
WO2000002050A1 (fr) *	1998-07-07	2000-01-13	Department Of Radiation Oncology, University Of Washington	Reactif trifonctionnel pour la conjugaison avec une biomolecule
AU5799199A (en) *	1998-09-04	2000-03-27	Immunomedics Inc.	Diagnosis of multidrug resistance in cancer and infectious lesions
CA2386029A1 (fr)	1999-09-28	2001-04-05	Gentest Corporation	P-glycoproteines provenant de <i>macaca fascicularis</i> et utilisations correspondantes
IT1319168B1 (it) *	2000-03-17	2003-09-26	Indena Spa	Derivati di condensazione ad attivita' antitumorale, loro metodo dipreparazione e formulazioni che li contengono.
US6855812B2 (en)	2001-03-19	2005-02-15	Becton, Dickinson And Company	P-glycoproteins and uses thereof
CN102112493B (zh)	2008-07-23	2015-04-01	韩美科学株式会社	包含具有三个官能性末端的非肽基聚合物的多肽复合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4722892A (en) *	1984-08-31	1988-02-02	Meares Claude F	Monoclonal antibodies against metal chelates
IL97459A0 (en) *	1990-03-09	1992-06-21	Hybritech Inc	Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent

1992
- 1992-07-17 AU AU24006/92A patent/AU2400692A/en not_active Abandoned
- 1992-07-17 WO PCT/US1992/006043 patent/WO1993002105A1/fr not_active Application Discontinuation
- 1992-07-17 CA CA002113578A patent/CA2113578A1/fr not_active Abandoned
- 1992-07-17 EP EP92916746A patent/EP0596011A1/fr not_active Ceased

Also Published As

Publication number	Publication date
CA2113578A1 (fr)	1993-02-04
WO1993002105A1 (fr)	1993-02-04
EP0596011A1 (fr)	1994-05-11

Publication	Publication Date	Title
US4863713A (en)	1989-09-05	Method and system for administering therapeutic and diagnostic agents
EP0550663B1 (fr)	1998-01-21	Anticorps modifies a temps de clairance regule
AU613318B2 (en)	1991-08-01	Affinity enhancement system
US5922847A (en)	1999-07-13	Methods of purifying hematopoietic cells using an antibody to a stem cell factor receptor
KR0135632B1 (ko)	1998-04-23	감염성 및 염증성 병변 표적용 항-백혈구 결합체 및 이를 함유하는 제제 및 키트
CA2031129C (fr)	2000-04-04	Anticorps chimere pour la detection et le traitement de lesions infectieuses et inflammatoires
JP2968474B2 (ja)	1999-10-25	抗−ヒト乳癌モノクローナル抗体を産生するハイブリドーマ
US5034223A (en)	1991-07-23	Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
USRE38008E1 (en)	2003-02-25	Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
PT94565B (pt)	1997-06-30	Novos anticorpos reactivos com carcinomas humanos
AU2400692A (en)	1993-02-23	Trifunctional compounds having specificity for multi-drug resistant cells
AU616161B2 (en)	1991-10-24	Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
CA2066031C (fr)	2001-02-27	Methodes de reduction de la retention non recherchee d'immunoconjugues et metabolites obtenus
Vacca et al.	1988	Imaging of human leukemic T‐Cell Xenografts in nude mice by radiolabeled monoclonal antibodies and F (ab') 2 fragments
US5250297A (en)	1993-10-05	Tumor-associated antigen, antibodies, compositions and uses therefor
US6440733B1 (en)	2002-08-27	Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel
JPH01502195A (ja)	1989-08-03	細胞毒性結合物の増強法
EP0256471A2 (fr)	1988-02-24	Conjugués cytotoxiques pour la thérapie du cancer
Li et al.	1990	Preparation of antigastric cancer monoclonal antibody MGb2-mitomycin C conjugate with improved antitumor activity
de Jonge et al.	1993	Radioimmunodetection of human small cell lung carcinoma xenografts in the nude rat using 111in-labelled monoclonal antibody MOC-31
EP0424107A1 (fr)	1991-04-24	Un antigène nouveau associé aux tumeurs
EP0356397A2 (fr)	1990-02-28	Anticorps monoclonaux et antigène de surface cellulaire de carcinome pulmonaire
KITAMURA et al.	1990	Binding, internalization and the cytotoxicity of monoclonal antibody A7-neocarzinostatin conjugates (A7-NCS) in target cells
Endo et al.	1984	Tumor imaging by monoclonal antibodies labeled with radioactive metal ions
PL168711B1 (pl)	1996-03-29	Sposób wytwarzania rekombinantu nowego przeciwciala obejmujacego region wiazaniantygenu mysiego przeciwciala monoklonalnego BR 96 PL